Company Overview: Scilex Holding Company

Business Focus:
Scilex Holding Company is a biopharmaceutical company engaged in the development, licensing, and commercialization of innovative pain management and specialty pharmaceutical products. The company leverages proprietary technologies, licensing agreements, and royalty arrangements to bring pharmaceutical products to market outside the United States and to generate revenue through product licensing, royalties, and strategic transactions.

Core Activities:

• Developing and commercializing pharmaceutical products such as Lidocaine-based products (including ZTlido and Gloperba) through licensing and partnership agreements with international licensees.
• Acquiring and managing rights to royalty streams from existing pharmaceutical products like ZTlido, Elyxyb, and Gloperba.
• Engaging in strategic financings, including issuance of convertible notes and warrants, to fund operations and acquisitions.
• Entering into licensing agreements for product development, manufacturing, and distribution, including domestic and international rights.

Key Agreements & Transactions:

• Has multiple licensing and sublicense agreements for products in pain management and dermatology, such as Lido (lidocaine), Elyxyb (ubrogepant), and Gloperba (colchicine).
• Holds royalty rights and security interests related to the sale of covered products and regulatory approvals.
• Has engaged in complex financings, including a registered convertible financing for $50 million in Tranche B notes, with various amendments and repayment strategies.
• Acquired rights through stock purchase agreements, including the purchase of equity securities from Sorrento, and solidified rights via security interests, guarantees, and subordinate agreements.

Operational Details:

• Number of issued shares as of March 25, 2025: 243,312,885 shares of common stock (pre-reverse split; 6,951,796 post-reverse split).
• Number of employees: Not specified.
• Revenue, net income, and customer count figures are not provided in the document.
• The company primarily generates revenue through licensing rights, royalty streams, and product sales in international markets.

Corporate Structure & Governance:

• Managed by a nine-member board, with divisions of responsibilities including audit, compensation, nomination, and strategic transactions.
• Has a well-defined internal governance framework, risk oversight processes, and various committees overseeing financial, operational, and strategic activities.
• Engages in extensive contractual arrangements for licensing, product development, and strategic financings.

Summary:
Scilex Holding Company operates within the pharmaceutical industry, focused on pain management and specialty pharmaceuticals, deriving revenue from licensing agreements and royalty rights. It is engaged in executing strategic financings and acquisitions to support its licensed product portfolio and international operations. The firm does not publicly disclose customer numbers, revenue, or net income figures within the provided document.